Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
GENE:
RANBP2 (RAN Binding Protein 2)
i
Other names:
RANBP2, RAN Binding Protein 2, NUP358, Acute Necrotizing Encephalopathy 1 (Autosomal Dominant), Nuclear Pore Complex Protein Nup358, E3 SUMO-Protein Ligase RanBP2, Ran-Binding Protein 2, 358 KDa Nucleoporin, Nucleoporin Nup358, Nucleoporin 358, ADANE, P270, E3 SUMO-Protein Transferase RanBP2, Transformation-Related Protein 2, RanBP2, IIAE3, ANE1, TRP1, TRP2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
5903
Associations
(7)
News
Trials
VERI cancer hierarchy
Reset Filters
RANBP2-ALK fusion
Soft Tissue Sarcoma
RANBP2-ALK fusion
Soft Tissue Sarcoma
doxorubicin hydrochloride
Resistant: C4 – Case Studies
doxorubicin hydrochloride
Resistant
:
C4
doxorubicin hydrochloride
Resistant: C4 – Case Studies
doxorubicin hydrochloride
Resistant
:
C4
RANBP2-ALK fusion
Soft Tissue Sarcoma
RANBP2-ALK fusion
Soft Tissue Sarcoma
crizotinib
Sensitive: C4 – Case Studies
crizotinib
Sensitive
:
C4
crizotinib
Sensitive: C4 – Case Studies
crizotinib
Sensitive
:
C4
RANBP2-ALK fusion
Chronic Myelomonocytic Leukemia
RANBP2-ALK fusion
Chronic Myelomonocytic Leukemia
cytarabine + daunorubicin
Sensitive: C4 – Case Studies
cytarabine + daunorubicin
Sensitive
:
C4
cytarabine + daunorubicin
Sensitive: C4 – Case Studies
cytarabine + daunorubicin
Sensitive
:
C4
RANBP2-ALK + TMEM217-ALK
Sarcoma
RANBP2-ALK + TMEM217-ALK
Sarcoma
crizotinib
Sensitive: C4 – Case Studies
crizotinib
Sensitive
:
C4
crizotinib
Sensitive: C4 – Case Studies
crizotinib
Sensitive
:
C4
RANBP2-ALK rearrangement + TNFRSF8 expression
Fibrosarcoma
RANBP2-ALK rearrangement + TNFRSF8 expression
Fibrosarcoma
ceritinib + brentuximab vedotin
Sensitive: D – Preclinical
ceritinib + brentuximab vedotin
Sensitive
:
D
ceritinib + brentuximab vedotin
Sensitive: D – Preclinical
ceritinib + brentuximab vedotin
Sensitive
:
D
RANBP2-ALK rearrangement + TNFRSF8 expression
Fibrosarcoma
RANBP2-ALK rearrangement + TNFRSF8 expression
Fibrosarcoma
crizotinib + brentuximab vedotin
Sensitive: D – Preclinical
crizotinib + brentuximab vedotin
Sensitive
:
D
crizotinib + brentuximab vedotin
Sensitive: D – Preclinical
crizotinib + brentuximab vedotin
Sensitive
:
D
RANBP2-ALK rearrangement + TNFRSF8 expression
Sarcoma
RANBP2-ALK rearrangement + TNFRSF8 expression
Sarcoma
brentuximab vedotin
Resistant: D – Preclinical
brentuximab vedotin
Resistant
:
D
brentuximab vedotin
Resistant: D – Preclinical
brentuximab vedotin
Resistant
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.